Flash Alert: Grab 388% Profits Now

By Ray BlancoPosted December 15, 2020

Psychedelic stocks are heating up! Already one of our positions is up over 50% since we bought in. And today, we have another stock with huge potential. Plus, book nearly 400% profits on one of our open positions!

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Supreme Court Gene Ruling Has Silver Lining for BioTime

By Patrick CoxPosted June 18, 2013

Whenever the Supreme Court hands down a ruling on some company's patent claim to a gene, markets tend to react, as investors worry about possibly far-reaching consequences. This isn't, of course, surprising. The science behind gene patents is complicated. Biotech patent law is just as confusing, but is even more inscrutable because it is decided by humans, rather than nature. At stake are thousands of gene patents.

The Next Plague: Zika Virus “Is Just the Tip of the Iceberg”

By Stephen PetranekPosted July 18, 2016

And the intriguing company in our portfolio that is developing treatment that may work no matter what the virus under attack is…

This Biotech Crashes But Doesn’t Burn

By Stephen PetranekPosted December 14, 2015

This biotech feel sharply after news of a failed trial. But don’t count it out just yet.

Another Breakthrough Week – Plus, Something I’m Not Pleased About…

By Patrick CoxPosted June 16, 2010

It's been a breakthrough week for our stem cell companies. I'll tell you about that first. Then I'll answer some criticisms another analyst has leveled at one of my favorite companies. I truly didn't want to do this, but my colleagues at Agora Financial have convinced me that it needs to be done. I will, but I'm not pleased about it!

Keep Calm and Carry On

By Stephen PetranekPosted January 26, 2015

Every time I make a recommendation when a stock has been soaring, I’m tempted to tell readers to wait a bit for a pullback. But I don’t. I’ve learned the hard way that although a pullback sometimes comes, the recommendations made in this portfolio are far more likely to go up, and to go up suddenly, than to go down. When a pullback does come, it’s impossible to know when to act. Is that price the bottom? Will the stock go down more tomorrow? Don’t ever let yourself get into that place

NanoViricides Updates

By Ray BlancoPosted July 30, 2013

In our last update, we mentioned NanoViricides' application for FDA orphan drug status for its dengue drug, DengueCide. Successfully receiving this designation, which is designed to encourage development of rare and tropical disease therapies, would greatly speed DengueCide's commercialization ramp. This would not only be a boon for NanoViricides and its investors, but for dengue patients as well.

Login